Caris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance

{
  "signal_id": "b055e2bf-54de-a09b-13a2-08d34a5537d1",
  "signal_type": "news",
  "signal_subtype": "has_revenue",
  "detected_at": "2026-08-05T20:05:00+00:00",
  "company": {
    "name": "Caris Life Sciences",
    "domain": "carislifesciences.com"
  },
  "data": {
    "url": "https://www.prnewswire.com/news-releases/caris-life-sciences-reports-second-quarter-2026-financial-results-and-increases-2026-revenue-guidance-302843876.html",
    "title": "Caris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance - PR Newswire",
    "excerpt": "Revenue growth of 45% driven by strong performance in molecular profiling services, including approximately 59,200 clinical cases, consisting of over 114,000 whole exome/whole transcriptome tests with over 345,000 total oncology tests Raises 2026 revenue guidance to $1.03 to $1.04 billion, representing growth of 27% to 28% IRVING, Texas , Aug. 5, 2026 /PRNewswire/ -- Caris Life Sciences , Inc. (Nasdaq: CAI ), a leading TechBio company actively developing and commercializing solutions to transform healthcare, today reported financial results for the quarter ended June 30, 2026. Second Quarter 2026 Financial Highlights \"This was a record quarter, with approximately 59,200 clinical cases, up more than 12% sequentially, reflecting sustained demand and the payoff from investments in our commercial engine,\" said David Dean Halbert , Founder, Chairman and CEO of Caris Life Sciences. \"Our comprehensive approach gives every case real molecular depth, across more than 1.13 million patients with AI trained on it, that depth is what powers Caris Detect. And Detect doesn't stop at finding cancer early, through what we call the Mutational Cleanse, we plan to turn an early signal into personalized immune targets, moving from early detection to early interception. It all comes back to one thing: making precision medicine a reality for every patient.\" Recent Operating Highlights Second Quarter...",
    "summary": "Caris Life Sciences reported total revenue of $263.7 million for the second quarter ended June 30, 2026, a 45% increase year-over-year.",
    "location": "Irving, Texas, USA",
    "planning": false,
    "image_url": "https://mmx.prnewswire.com/media/MS863020/Caris-Life-Sciences-Logo.jpg?id=OA2825009&p=facebook",
    "confidence": 0.95,
    "published_at": "2026-08-05T20:05:00Z",
    "location_data": [
      {
        "city": "Irving",
        "state": "Texas",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-06-30",
    "article_sentence": "Total revenue was $263.7 million for the three months ended June 30, 2026, compared to $181.4 million for the three months ended June 30, 2025, an increase of $82.3 million, or 45%.",
    "amount_normalized": 263700000
  }
}

curl https://signals.autobound.ai/v1/signals/b055e2bf-54de-a09b-13a2-08d34a5537d1 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"carislifesciences.com","limit":20}'